Adaptive Biotechnologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Adaptive Biotechnologies 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

CEO
Chad Robins
CEOChad Robins
Employees
624
Employees624
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2009
Founded2009
Employees
624
Employees624

ADPT Key Statistics

Market cap
3.81B
Market cap3.81B
Price-Earnings ratio
-55.33
Price-Earnings ratio-55.33
Dividend yield
Dividend yield
Average volume
2.91M
Average volume2.91M
High today
$24.57
High today$24.57
Low today
$22.41
Low today$22.41
Open price
$24.40
Open price$24.40
Volume
2.99M
Volume2.99M
52 Week high
$24.57
52 Week high$24.57
52 Week low
$10.02
52 Week low$10.02

Stock Snapshot

The current Adaptive Biotechnologies(ADPT) stock price is $23.02, with a market capitalization of 3.81B. The stock trades at a price-to-earnings (P/E) ratio of -55.33.

On 2026-08-01, Adaptive Biotechnologies(ADPT) stock traded between a low of $22.41 and a high of $24.57. Shares are currently priced at $23.02, which is +2.7% above the low and -6.3% below the high.

The Adaptive Biotechnologies(ADPT)'s current trading volume is 2.99M, compared to an average daily volume of 2.91M.

During the past year, Adaptive Biotechnologies(ADPT) stock moved between $10.02 at its lowest and $24.57 at its peak.

During the past year, Adaptive Biotechnologies(ADPT) stock moved between $10.02 at its lowest and $24.57 at its peak.

ADPT News

Investing.com 2d
Adaptive Biotechnologies stock hits 52-week high at 23.25 USD - Investing.com

...

Adaptive Biotechnologies stock hits 52-week high at 23.25 USD - Investing.com
TipRanks 2d
Adaptive Biotechnologies price target raised to $27 from $25 at JPMorgan

JPMorgan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27 from $25 and keeps an Overweight rating on the shares. Unlock powerful invest...

TipRanks 3d
Adaptive Biotechnologies CSO Transitions to Strategic Consulting Role

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More ADPT News

TipRanks 3d
Adaptive Biotechnologies reports Q2 EPS (25c), consensus (13c)

Reports Q2 revenue $71.6M, consensus $65.45M. Cash, cash equivalents and marketable securities was $371.7M as of June 30, inclusive of $15.1M of cash and cash e...

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.